ClinicalTrials.gg
CompletedNCT02499783Updated Jan 4, 2019Results posted

Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease

A Phase 3 interventional study of adalimumab and placebo in Crohn's Disease, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-01-04.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
205
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
14th of 42
205 · median 143
Started
2015
with 1 other
Phase 3
22 of 42
none open now
Registered
30th of 42
by date
Lead sponsor
6 of 42
AbbVie

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 14th largest by enrollment, is one of 2 that started in 2015, is one of 22 in phase 3, and was the 30th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of adalimumab induction and maintenance treatment in subjects with moderately to severely active Crohn's disease in China.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • China
  • Tumor necrosis factor (TNF)-alpha
  • Biologic
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects of Chinese descent with full Chinese parentage.
  • Diagnosis of Crohn's disease (CD) for at least 3 months prior to Week 0.
  • Crohn's Disease Activity Index (CDAI) greater than or equal to 220 and less than or equal to 450 despite treatment with oral and/or .
  • Subject has a negative Tuberculosis (TB) Screening Assessment.
  • Subject has elevated high sensitivity C-reactive protein (hs-CRP) during the Screening Period.

Exclusion criteria

Exclusion Criteria:

  • Subject with ulcerative colitis or indeterminate colitis.
  • Subject who has had a surgical bowel resection within the past 6 months or who is planning any resection at any time point in the future.
  • Subject with an ostomy or ileoanal pouch.
  • Subject who has short bowel syndrome.
  • Subject with symptomatic known obstructive strictures.
  • Subject with an internal or external fistula (with the exception of an anal fistula without abscess).
  • Active, or chronic or recurring infections, or active tuberculosis.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
205 participants (actual)

Study arms

  • Experimental
    Placebo Induction Regimen

    Double-blind period (Weeks 0-8): Placebo at Weeks 0 and 2, followed by adalimumab 160 mg at Week 4, 80 mg at Week 6. Open label period: adalimumab 40 mg every other week (eow) from Week 8 through last dose at Week 24.

    Biological: adalimumab · Other: placebo

  • Experimental
    Adalimumab Induction Regimen

    Double-blind period (Weeks 0-8): adalimumab 160 mg at Weeks 0 and 80 mg at Week 2, followed by adalimumab 40 mg at Week 4 and Week 6. Open label period: adalimumab 40 mg eow from Week 8 through last dose at Week 24.

    Biological: adalimumab

Interventions

  • Biologicaladalimumab

    subcutaneous injections of adalimumab

    Also known as: Humira

  • Otherplacebo

    subcutaneous injections of placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 4

Secondary outcomes

  1. Percentage of Participants Who Achieved Clinical Remission at Week 26 (CDAI < 150) in Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 26

  2. Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus a Reduction in Hs-CRP of at Least 50% From Baseline at Week 4

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 4

  3. Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus a Reduction in Hs-CRP of At Least 50% From Baseline at Week 26 in Participants Who Achieved Clinical Response Plus at Least 30% Reduction in Hs-CRP From Baseline at Week 8

    Clinical response is defined as a decrease in CDAI ≥ 70 Points from Baseline CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 26

  4. Percentage of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission at Week 26 in Participants Who Were Taking Steroids at Baseline and Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 26

  5. Percentage of Participants Who Discontinued Corticosteroid Use and Achieved CDAI < 150 Plus a Reduction in Hs-CRP of ≥ 50% From Baseline (BL) at Week 26 in Participants Taking Steroids at BL and Who Achieved CDAI Decrease and Hs-CRP Reduction at Week 8

    Percentage of participants who discontinued corticosteroid use and achieved clinical remission (CDAI \< 150) plus a reduction in hs-CRP of at least 50% from Baseline at Week 26 in participants who were taking steroids at Baseline and who achieved clinical response (decrease in CDAI of ≥ 70 points from Baseline) plus a reduction in hs-CRP of ≥ 30% From Baseline at Week 8. CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 26

  6. Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 4

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 4

  7. Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Plus a Reduction in Hs-CRP of at Least 30% From Baseline at Week 4

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 4

  8. Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) and Hs-CRP < 3 mg/L at Week 4

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 4

  9. Percentage of Participants Who Achieved Clinical Remission (CDAI < 150), Hs-CRP < 3 mg/L at Week 26 in Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 26

  10. Percentage of Participants Who Achieved Inflammatory Bowel Disease Questionnaire (IBDQ) Remission (IBDQ ≥ 170 Points) at Week 4

    The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of the responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.

    Time frame: Week 4

  11. Percentage of Participants Who Achieved IBDQ Remission (IBDQ ≥ 170 Points) at Week 26 in Participants With Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8

    The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of the responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life. CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 26

  12. Change From Baseline in Fecal Calprotectin Level at Week 4

    Time frame: Baseline, Week 4

  13. Percentage of Participants Who Achieved Clinical Remission (CDAI < 150), Hs-CRP < 3 mg/L and Fecal Calprotectin < 250 μg/g at Week 4

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 4

  14. Percentage of Participants Who Achieved Clinical Remission (CDAI < 150), Hs-CRP < 3 mg/L and Fecal Calprotectin < 250 μg/g at Week 26 in Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

    Time frame: Week 26

  15. Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Over Double-Blind Weeks 0-4

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment.

    Time frame: Weeks 2, 4

  16. Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Over Time (Any Adalimumab Set)

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment. (Note: the analysis window for the 'Any Adalimumab Set' is different from that used for the ITT population. For the Any Adalimumab Set, the Baseline Visit date is the date when the first dose of adalimumab was received, and was counted as Day 1 or Week 0.)

    Time frame: Baseline (Week 0 of adalimumab), Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26

  17. Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus A Reduction in Hs-CRP of at Least 50% From Baseline Over Double-Blind Weeks 0-4

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment.

    Time frame: Weeks 2, 4

  18. Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus a Reduction in Hs-CRP of at Least 50% From Baseline Over Time (Any Adalimumab Set)

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment. (Note: the analysis window for the 'Any Adalimumab Set' is different from that used for the ITT population. For the Any Adalimumab Set, the Baseline Visit date is the date when the first dose of adalimumab was received, and was counted as Day 1 or Week 0.)

    Time frame: Weeks 2, 4, 6, 8, 12, 16, 20, 26

  19. Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Over Double-Blind Weeks 0-4

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment.

    Time frame: Weeks 2, 4

  20. Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Over Time (Any Adalimumab Set)

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment. (Note: the analysis window for the 'Any Adalimumab Set' is different from that used for the ITT population. For the Any Adalimumab Set, the Baseline Visit date is the date when the first dose of adalimumab was received, and was counted as Day 1 or Week 0.)

    Time frame: Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26

  21. Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Plus a Reduction in Hs-CRP of at Least 30% From Baseline Over Double-Blind Weeks 0-4

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment.

    Time frame: Weeks 2, 4

  22. Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Plus a Reduction in Hs-CRP of at Least 30% From Baseline Over Time (Any Adalimumab Set)

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment. (Note: the analysis window for the 'Any Adalimumab Set' is different from that used for the ITT population. For the Any Adalimumab Set, the Baseline Visit date is the date when the first dose of adalimumab was received, and was counted as Day 1 or Week 0.)

    Time frame: Weeks 2, 4, 6, 8, 12, 16, 20, 26

  23. Change From Baseline in CDAI Over Double-Blind Weeks 0-4

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment.

    Time frame: Baseline, Weeks 2, 4

  24. Change From Baseline in CDAI Over Time (Any Adalimumab Set)

    CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment. (Note: the analysis window for the 'Any Adalimumab Set' is different from that used for the ITT population. For the Any Adalimumab Set, the Baseline Visit date is the date when the first dose of adalimumab was received, and was counted as Day 1 or Week 0.)

    Time frame: Baseline (Week 0 of adalimumab), Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26

  25. Change From Baseline in Hs-CRP Level Over Double-Blind Weeks 0-4

    The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment.

    Time frame: Baseline, Weeks 2, 4

  26. Change From Baseline in Hs-CRP Level Over Time (Any Adalimumab Set)

    The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment. (Note: the analysis window for the 'Any Adalimumab Set' is different from that used for the ITT population. For the Any Adalimumab Set, the Baseline Visit date is the date when the first dose of adalimumab was received, and was counted as Day 1 or Week 0.)

    Time frame: Baseline (Week 0 of adalimumab), Weeks 2, 4, 6, 8, 12, 16 20, 26

  27. Change From Baseline in Fecal Calprotectin Level Over Time (Any Adalimumab Set)

    The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment.

    Time frame: Baseline (Week 0 of adalimumab), Weeks 4, 8, 26

07

Results

Posted Jan 4, 2019

Participant flow

DB Period/Placebo-Controlled: Weeks 0-4
Participant flow — DB Period/Placebo-Controlled: Weeks 0-4
MilestoneDouble-Blind (DB) Period: Adalimumab 160/80/40 mgDB Period: Placebo Followed by Adalimumab 160/80 mgOpen-Label (OL) Period: Adalimumab 40 mg
Started1021030
Completed98980
Not completed450
Withdrew: Adverse event240
Withdrew: Withdrew consent100
Withdrew: Other110
DB Period: Weeks 0-8
Participant flow — DB Period: Weeks 0-8
MilestoneDouble-Blind (DB) Period: Adalimumab 160/80/40 mgDB Period: Placebo Followed by Adalimumab 160/80 mgOpen-Label (OL) Period: Adalimumab 40 mg
Started1021030
Completed92960
Not completed1070
Withdrew: Adverse event860
Withdrew: Withdrew consent100
Withdrew: Other110
Open Label Period: Weeks 8 to 26
Participant flow — Open Label Period: Weeks 8 to 26
MilestoneDouble-Blind (DB) Period: Adalimumab 160/80/40 mgDB Period: Placebo Followed by Adalimumab 160/80 mgOpen-Label (OL) Period: Adalimumab 40 mg
Started00188
Completed00159
Not completed0029
Withdrew: Adverse event0016
Withdrew: Withdrew consent002
Withdrew: Lack of efficacy009
Withdrew: Subject noncompliance002

Outcome measures

PrimaryPercentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4
percentage of participantsDouble-Blind Period, Weeks 0 to 4: PlaceboDouble-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 46.837.3
Statistical analysis
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted risk difference: 30.4 · 95% CI 19.2 to 41.7Risk difference = (adalimumab 160/80 mg - placebo). Stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.
SecondaryPercentage of Participants Who Achieved Clinical Remission at Week 26 (CDAI < 150) in Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission at Week 26 (CDAI < 150) in Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8
percentage of participantsAll Participants
Percentage of Participants Who Achieved Clinical Remission at Week 26 (CDAI < 150) in Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 864.6
Statistical analysis
  • All Participants · One Sample Exact Test · p = < 0.001 · Risk difference compared to 30%: 34.6 · 95% CI 26.2 to 42.4The one sample Exact test was performed by comparing it to the clinically meaningful remission rate of 30%.
SecondaryPercentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus a Reduction in Hs-CRP of at Least 50% From Baseline at Week 4

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus a Reduction in Hs-CRP of at Least 50% From Baseline at Week 4
percentage of participantsDouble-Blind Period, Weeks 0 to 4: PlaceboDouble-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus a Reduction in Hs-CRP of at Least 50% From Baseline at Week 4033.3
Statistical analysis
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · Cochran-Mantel-Haenszel · p = < 0.001 (Based on Cochran-Mantel-Haenszel test stratified by be stratified by Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline.) · Adjusted risk difference: 33.4 · 95% CI 23.2 to 43.6Risk difference = (adalimumab 160/80 mg - placebo). Based on Cochran-Mantel-Haenszel test stratified by be stratified by Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline.
SecondaryPercentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus a Reduction in Hs-CRP of At Least 50% From Baseline at Week 26 in Participants Who Achieved Clinical Response Plus at Least 30% Reduction in Hs-CRP From Baseline at Week 8

Clinical response is defined as a decrease in CDAI ≥ 70 Points from Baseline CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus a Reduction in Hs-CRP of At Least 50% From Baseline at Week 26 in Participants Who Achieved Clinical Response Plus at Least 30% Reduction in Hs-CRP From Baseline at Week 8
percentage of participantsAll Participants
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus a Reduction in Hs-CRP of At Least 50% From Baseline at Week 26 in Participants Who Achieved Clinical Response Plus at Least 30% Reduction in Hs-CRP From Baseline at Week 855.0
SecondaryPercentage of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission at Week 26 in Participants Who Were Taking Steroids at Baseline and Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission at Week 26 in Participants Who Were Taking Steroids at Baseline and Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8
percentage of participantsAll Participants
Percentage of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission at Week 26 in Participants Who Were Taking Steroids at Baseline and Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 862.8
SecondaryPercentage of Participants Who Discontinued Corticosteroid Use and Achieved CDAI < 150 Plus a Reduction in Hs-CRP of ≥ 50% From Baseline (BL) at Week 26 in Participants Taking Steroids at BL and Who Achieved CDAI Decrease and Hs-CRP Reduction at Week 8

Percentage of participants who discontinued corticosteroid use and achieved clinical remission (CDAI \< 150) plus a reduction in hs-CRP of at least 50% from Baseline at Week 26 in participants who were taking steroids at Baseline and who achieved clinical response (decrease in CDAI of ≥ 70 points from Baseline) plus a reduction in hs-CRP of ≥ 30% From Baseline at Week 8. CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Discontinued Corticosteroid Use and Achieved CDAI < 150 Plus a Reduction in Hs-CRP of ≥ 50% From Baseline (BL) at Week 26 in Participants Taking Steroids at BL and Who Achieved CDAI Decrease and Hs-CRP Reduction at Week 8
percentage of participantsAll Participants
Percentage of Participants Who Discontinued Corticosteroid Use and Achieved CDAI < 150 Plus a Reduction in Hs-CRP of ≥ 50% From Baseline (BL) at Week 26 in Participants Taking Steroids at BL and Who Achieved CDAI Decrease and Hs-CRP Reduction at Week 857.6
SecondaryPercentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 4

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 4
percentage of participantsDouble-Blind Period, Weeks 0 to 4: PlaceboDouble-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg
Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 427.267.6
Statistical analysis
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · Cochran-Mantel-Haenszel · p = < 0.001 (Based on Cochran-Mantel-Haenszel test stratified by be stratified by Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline.) · Adjusted risk difference: 40.4 · 95% CI 26.7 to 54.2Risk difference = (adalimumab 160/80 mg - placebo). Based on Cochran-Mantel-Haenszel test stratified by be stratified by Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline.
SecondaryPercentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Plus a Reduction in Hs-CRP of at Least 30% From Baseline at Week 4

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Plus a Reduction in Hs-CRP of at Least 30% From Baseline at Week 4
percentage of participantsDouble-Blind Period, Weeks 0 to 4: PlaceboDouble-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg
Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Plus a Reduction in Hs-CRP of at Least 30% From Baseline at Week 411.761.8
Statistical analysis
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · Cochran-Mantel-Haenszel · p = < 0.001 (Based on Cochran-Mantel-Haenszel test stratified by be stratified by Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline.) · Adjusted risk difference: 50.2 · 95% CI 36.9 to 63.5Risk difference = (adalimumab 160/80 mg - placebo). Based on Cochran-Mantel-Haenszel test stratified by be stratified by Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline.
SecondaryPercentage of Participants Who Achieved Clinical Remission (CDAI < 150) and Hs-CRP < 3 mg/L at Week 4

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) and Hs-CRP < 3 mg/L at Week 4
percentage of participantsDouble-Blind Period, Weeks 0 to 4: PlaceboDouble-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) and Hs-CRP < 3 mg/L at Week 4027.5
Statistical analysis
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · Cochran-Mantel-Haenszel · p = < 0.001 (Based on Cochran-Mantel-Haenszel test stratified by be stratified by Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline.) · Adjusted risk difference: 27.6 · 95% CI 18.2 to 37.0Risk difference = (adalimumab 160/80 mg - placebo). Based on Cochran-Mantel-Haenszel test stratified by be stratified by Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline.
SecondaryPercentage of Participants Who Achieved Clinical Remission (CDAI < 150), Hs-CRP < 3 mg/L at Week 26 in Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150), Hs-CRP < 3 mg/L at Week 26 in Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8
percentage of participantsAll Participants
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150), Hs-CRP < 3 mg/L at Week 26 in Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 836.8
SecondaryPercentage of Participants Who Achieved Inflammatory Bowel Disease Questionnaire (IBDQ) Remission (IBDQ ≥ 170 Points) at Week 4

The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of the responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Inflammatory Bowel Disease Questionnaire (IBDQ) Remission (IBDQ ≥ 170 Points) at Week 4
percentage of participantsDouble-Blind Period, Weeks 0 to 4: PlaceboDouble-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg
Percentage of Participants Who Achieved Inflammatory Bowel Disease Questionnaire (IBDQ) Remission (IBDQ ≥ 170 Points) at Week 420.440.2
Statistical analysis
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · Cochran-Mantel-Haenszel · p = 0.002 (Based on Cochran-Mantel-Haenszel test stratified by be stratified by Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline.) · Adjusted risk difference: 19.6 · 95% CI 7.1 to 32.1Risk difference = (adalimumab 160/80 mg - placebo). Based on Cochran-Mantel-Haenszel test stratified by be stratified by Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline.
SecondaryPercentage of Participants Who Achieved IBDQ Remission (IBDQ ≥ 170 Points) at Week 26 in Participants With Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8

The IBDQ is a self-administered 32-item questionnaire to evaluate quality of life across 4 dimensional scores: bowel, systemic, social and emotional. Responses to each question range from 1 (severe problem) to 7 (normal health). Total IBDQ score is the sum of the responses to the individual IBDQ questions, and ranges from 32 to 224 with higher scores indicating a better quality of life. CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved IBDQ Remission (IBDQ ≥ 170 Points) at Week 26 in Participants With Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8
percentage of participantsAll Participants
Percentage of Participants Who Achieved IBDQ Remission (IBDQ ≥ 170 Points) at Week 26 in Participants With Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 851.4
SecondaryChange From Baseline in Fecal Calprotectin Level at Week 4
Time frame:
Baseline, Week 4
Reported as:
Mean · μg/g
Change From Baseline in Fecal Calprotectin Level at Week 4
μg/gDouble-Blind Period, Weeks 0 to 4: PlaceboDouble-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg
Change From Baseline in Fecal Calprotectin Level at Week 4-66.3 ± 844.89-499.5 ± 868.62
Statistical analysis
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · ANCOVA · p = < 0.001 (P-value for test of difference between adalimumab and placebo for mean change from Baseline using ANCOVA with Treatment, Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline, and Baseline value as covariate.) · Least squares mean difference: -385.2 · 95% CI -598.81 to -171.50
SecondaryPercentage of Participants Who Achieved Clinical Remission (CDAI < 150), Hs-CRP < 3 mg/L and Fecal Calprotectin < 250 μg/g at Week 4

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150), Hs-CRP < 3 mg/L and Fecal Calprotectin < 250 μg/g at Week 4
percentage of participantsDouble-Blind Period, Weeks 0 to 4: PlaceboDouble-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150), Hs-CRP < 3 mg/L and Fecal Calprotectin < 250 μg/g at Week 409.8
Statistical analysis
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · Cochran-Mantel-Haenszel · p = 0.001 (Based on Cochran-Mantel-Haenszel test stratified by be stratified by Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline.) · Adjusted risk difference: 9.8 · 95% CI 3.9 to 15.8Risk difference = (adalimumab 160/80 mg - placebo). Based on Cochran-Mantel-Haenszel test stratified by be stratified by Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline.
SecondaryPercentage of Participants Who Achieved Clinical Remission (CDAI < 150), Hs-CRP < 3 mg/L and Fecal Calprotectin < 250 μg/g at Week 26 in Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150), Hs-CRP < 3 mg/L and Fecal Calprotectin < 250 μg/g at Week 26 in Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8
percentage of participantsAll Participants
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150), Hs-CRP < 3 mg/L and Fecal Calprotectin < 250 μg/g at Week 26 in Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 816.0
SecondaryPercentage of Participants Who Achieved Clinical Remission (CDAI < 150) Over Double-Blind Weeks 0-4

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment.

Time frame:
Weeks 2, 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Over Double-Blind Weeks 0-4
percentage of participantsDouble-Blind Period, Weeks 0 to 4: PlaceboDouble-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg
Week 27.826.5
Week 46.837.3
Statistical analysis
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · Cochran-Mantel-Haenszel · p = < 0.001 (Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.) · Adjusted risk difference: 18.4 · 95% CI 8.2 to 28.6Risk difference = (adalimumab 160/80 mg - placebo). Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · Cochran-Mantel-Haenszel · p = < 0.001 (Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.) · Adjusted risk difference: 30.4 · 95% CI 19.2 to 41.7Risk difference = (adalimumab 160/80 mg - placebo). Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.
SecondaryPercentage of Participants Who Achieved Clinical Remission (CDAI < 150) Over Time (Any Adalimumab Set)

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment. (Note: the analysis window for the 'Any Adalimumab Set' is different from that used for the ITT population. For the Any Adalimumab Set, the Baseline Visit date is the date when the first dose of adalimumab was received, and was counted as Day 1 or Week 0.)

Time frame:
Baseline (Week 0 of adalimumab), Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Over Time (Any Adalimumab Set)
percentage of participantsAll Participants
Baseline3.0
Week 231.5
Week 440.0
Week 648.0
Week 855.5
Week 1045.5
Week 1256.5
Week 1451.5
Week 1656.0
Week 1848.5
Week 2053.0
Week 2252.5
Week 2449.0
Week 2653.9
SecondaryPercentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus A Reduction in Hs-CRP of at Least 50% From Baseline Over Double-Blind Weeks 0-4

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment.

Time frame:
Weeks 2, 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus A Reduction in Hs-CRP of at Least 50% From Baseline Over Double-Blind Weeks 0-4
percentage of participantsDouble-Blind Period, Weeks 0 to 4: PlaceboDouble-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg
Week 21.022.5
Week 4033.3
Statistical analysis
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · Cochran-Mantel-Haenszel · p = < 0.001 (Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.) · Adjusted risk difference: 21.4 · 95% CI 12.6 to 30.2Risk difference = (adalimumab 160/80 mg - placebo). Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · Cochran-Mantel-Haenszel · p = < 0.001 (Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.) · Adjusted risk difference: 33.4 · 95% CI 23.2 to 43.6Risk difference = (adalimumab 160/80 mg - placebo). Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.
SecondaryPercentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus a Reduction in Hs-CRP of at Least 50% From Baseline Over Time (Any Adalimumab Set)

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment. (Note: the analysis window for the 'Any Adalimumab Set' is different from that used for the ITT population. For the Any Adalimumab Set, the Baseline Visit date is the date when the first dose of adalimumab was received, and was counted as Day 1 or Week 0.)

Time frame:
Weeks 2, 4, 6, 8, 12, 16, 20, 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus a Reduction in Hs-CRP of at Least 50% From Baseline Over Time (Any Adalimumab Set)
percentage of participantsAll Participants
Week 227.5
Week 436.0
Week 626.0
Week 845.0
Week 1243.5
Week 1644.5
Week 2042.0
Week 2639.2
SecondaryPercentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Over Double-Blind Weeks 0-4

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment.

Time frame:
Weeks 2, 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Over Double-Blind Weeks 0-4
percentage of participantsDouble-Blind Period, Weeks 0 to 4: PlaceboDouble-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg
Week 222.344.1
Week 427.267.6
Statistical analysis
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · Cochran-Mantel-Haenszel · p = 0.001 (Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.) · Adjusted risk difference: 21.7 · 95% CI 8.7 to 34.6Risk difference = (adalimumab 160/80 mg - placebo). Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · Cochran-Mantel-Haenszel · p = < 0.001 (Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.) · Adjusted risk difference: 40.4 · 95% CI 26.7 to 54.2Risk difference = (adalimumab 160/80 mg - placebo). Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.
SecondaryPercentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Over Time (Any Adalimumab Set)

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment. (Note: the analysis window for the 'Any Adalimumab Set' is different from that used for the ITT population. For the Any Adalimumab Set, the Baseline Visit date is the date when the first dose of adalimumab was received, and was counted as Day 1 or Week 0.)

Time frame:
Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Over Time (Any Adalimumab Set)
percentage of participantsAll Participants
Week 245.0
Week 459.0
Week 660.0
Week 864.5
Week 1054.5
Week 1258.0
Week 1454.5
Week 1658.0
Week 1849.5
Week 2054.5
Week 2250.0
Week 2452.9
Week 2659.8
SecondaryPercentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Plus a Reduction in Hs-CRP of at Least 30% From Baseline Over Double-Blind Weeks 0-4

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment.

Time frame:
Weeks 2, 4
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Plus a Reduction in Hs-CRP of at Least 30% From Baseline Over Double-Blind Weeks 0-4
percentage of participantsDouble-Blind Period, Weeks 0 to 4: PlaceboDouble-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg
Week 28.740.2
Week 411.761.8
Statistical analysis
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · Cochran-Mantel-Haenszel · p = < 0.001 (Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.) · Adjusted risk difference: 31.4 · 95% CI 19.6 to 43.2Risk difference = (adalimumab 160/80 mg - placebo). Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · Cochran-Mantel-Haenszel · p = < 0.001 (Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.) · Adjusted risk difference: 50.2 · 95% CI 36.9 to 63.5Risk difference = (adalimumab 160/80 mg - placebo). Based on Cochran-Mantel-Haenszel test stratified by Crohn's disease severity (CDAI \<= 300 and CDAI \>300) at baseline and corticosteroid use at baseline.
SecondaryPercentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Plus a Reduction in Hs-CRP of at Least 30% From Baseline Over Time (Any Adalimumab Set)

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment. (Note: the analysis window for the 'Any Adalimumab Set' is different from that used for the ITT population. For the Any Adalimumab Set, the Baseline Visit date is the date when the first dose of adalimumab was received, and was counted as Day 1 or Week 0.)

Time frame:
Weeks 2, 4, 6, 8, 12, 16, 20, 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Plus a Reduction in Hs-CRP of at Least 30% From Baseline Over Time (Any Adalimumab Set)
percentage of participantsAll Participants
Week 241.5
Week 455.0
Week 635.5
Week 855.5
Week 1249.5
Week 1651.0
Week 2045.5
Week 2652.0
SecondaryChange From Baseline in CDAI Over Double-Blind Weeks 0-4

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment.

Time frame:
Baseline, Weeks 2, 4
Reported as:
Mean · units on a scale
Change From Baseline in CDAI Over Double-Blind Weeks 0-4
units on a scaleDouble-Blind Period, Weeks 0 to 4: PlaceboDouble-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg
Week 2-30.97 ± 53.699-73.66 ± 63.267
Week 4-38.22 ± 60.918-104.56 ± 67.325
Statistical analysis
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · ANCOVA · p = < 0.001 (P-value for test of difference between adalimumab and placebo for mean change from Baseline using ANCOVA with Treatment, Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline, and Baseline value as covariate.) · Least squares mean difference: -43.34 · 95% CI -59.39 to -27.30
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · ANCOVA · p = < 0.001 (P-value for test of difference between adalimumab and placebo for mean change from Baseline using ANCOVA with Treatment, Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline, and Baseline value as covariate.) · Least squares mean difference: -66.63 · 95% CI -84.20 to -49.06
SecondaryChange From Baseline in CDAI Over Time (Any Adalimumab Set)

CDAI is used to assess the symptoms of participants with Crohn's Disease. Scores generally range from 0 to 600, where remission of Crohn's disease is defined as CDAI \< 150, and very severe disease is defined as CDAI \> 450. The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment. (Note: the analysis window for the 'Any Adalimumab Set' is different from that used for the ITT population. For the Any Adalimumab Set, the Baseline Visit date is the date when the first dose of adalimumab was received, and was counted as Day 1 or Week 0.)

Time frame:
Baseline (Week 0 of adalimumab), Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26
Reported as:
Mean · units on a scale
Change From Baseline in CDAI Over Time (Any Adalimumab Set)
units on a scaleAll Participants
Week 2-67.31 ± 67.268
Week 4-92.60 ± 74.666
Week 6-103.62 ± 79.094
Week 8-115.96 ± 83.900
Week 10-122.51 ± 82.991
Week 12-131.55 ± 76.754
Week 14-136.85 ± 76.459
Week 16-143.56 ± 72.597
Week 18-140.40 ± 77.473
Week 20-147.54 ± 72.352
Week 22-143.99 ± 77.972
Week 24-182.01 ± 54.588
Week 26-178.74 ± 54.277
SecondaryChange From Baseline in Hs-CRP Level Over Double-Blind Weeks 0-4

The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment.

Time frame:
Baseline, Weeks 2, 4
Reported as:
Mean · mg/L
Change From Baseline in Hs-CRP Level Over Double-Blind Weeks 0-4
mg/LDouble-Blind Period, Weeks 0 to 4: PlaceboDouble-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg
Week 2-4.149 ± 22.1944-16.474 ± 25.5491
Week 4-1.131 ± 18.8392-16.670 ± 19.9088
Statistical analysis
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · ANCOVA · p = < 0.001 (P-value for test of difference between adalimumab and placebo for mean change from Baseline using ANCOVA with Treatment, Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline, and Baseline value as covariate.) · Least squares mean difference: -13.921 · 95% CI -19.183 to -8.659
  • Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg · ANCOVA · p = < 0.001 (P-value for test of difference between adalimumab and placebo for mean change from Baseline using ANCOVA with Treatment, Crohn's disease severity (CDAI \<= 300, \> 300) at Baseline and corticosteroid use at Baseline, and Baseline value as covariate.) · Least squares mean difference: -16.844 · 95% CI -21.206 to -12.483
SecondaryChange From Baseline in Hs-CRP Level Over Time (Any Adalimumab Set)

The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment. (Note: the analysis window for the 'Any Adalimumab Set' is different from that used for the ITT population. For the Any Adalimumab Set, the Baseline Visit date is the date when the first dose of adalimumab was received, and was counted as Day 1 or Week 0.)

Time frame:
Baseline (Week 0 of adalimumab), Weeks 2, 4, 6, 8, 12, 16 20, 26
Reported as:
Mean · mg/L
Change From Baseline in Hs-CRP Level Over Time (Any Adalimumab Set)
mg/LAll Participants
Week 2-16.923 ± 23.8242
Week 4-17.064 ± 21.8366
Week 6-12.295 ± 20.9586
Week 8-14.565 ± 18.5093
Week 12-13.527 ± 19.9087
Week 16-13.504 ± 18.1452
Week 20-11.921 ± 18.4776
Week 26-12.308 ± 14.4531
SecondaryChange From Baseline in Fecal Calprotectin Level Over Time (Any Adalimumab Set)

The analysis over time was performed for the DB placebo-controlled period (Week 0 to Week 4), with comparisons between active treatment and placebo groups. The analysis over time was also performed for Any Adalimumab set (the entire study on or after the first dose of adalimumab), with only summary statistics for adalimumab treatment.

Time frame:
Baseline (Week 0 of adalimumab), Weeks 4, 8, 26
Reported as:
Mean · μg/g
Change From Baseline in Fecal Calprotectin Level Over Time (Any Adalimumab Set)
μg/gAll Participants
Week 4-425.7 ± 940.04
Week 8-529.6 ± 913.50
Week 26-475.6 ± 978.07

Adverse events

Collected over Treatment-emergent adverse events (TEAEs): from first dose of study drug through last dose (Week 24) plus 70 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Placebo Weeks 0-40/103 (0%)1/103 (1%)18/103 (17.5%)
Double-Blind Adalimumab 160/80 mg Weeks 0-40/102 (0%)2/102 (2%)25/102 (24.5%)
Any Adalimumab0/200 (0%)36/200 (18%)137/200 (68.5%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventDouble-Blind Placebo Weeks 0-4Double-Blind Adalimumab 160/80 mg Weeks 0-4Any Adalimumab
CROHN'S DISEASEGastrointestinal disorders0/1030/10217/200
ANAEMIABlood and lymphatic system disorders0/1031/1022/200
ABDOMINAL PAINGastrointestinal disorders0/1030/1022/200
PERITONITISInfections and infestations0/1030/1022/200
ABORTION INDUCEDSurgical and medical procedures0/1031/1021/200
LOWER GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders1/1030/1020/200
ABDOMINAL MASSGastrointestinal disorders0/1030/1021/200
ANAL FISTULAGastrointestinal disorders0/1030/1021/200
ENTEROVESICAL FISTULAGastrointestinal disorders0/1030/1021/200
GASTROINTESTINAL FISTULAGastrointestinal disorders0/1030/1021/200
Most frequent other events
Showing 10 of 11
Most frequent other events
EventDouble-Blind Placebo Weeks 0-4Double-Blind Adalimumab 160/80 mg Weeks 0-4Any Adalimumab
WHITE BLOOD CELL COUNT DECREASEDInvestigations1/1036/10239/200
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations5/1031/10223/200
LEUKOPENIABlood and lymphatic system disorders1/1033/10222/200
VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations3/1034/10220/200
COUGHRespiratory, thoracic and mediastinal disorders0/1035/10216/200
PYREXIAGeneral disorders4/1031/10215/200
INFLUENZAInfections and infestations1/1032/10213/200
MYCOBACTERIUM TUBERCULOSIS COMPLEX TEST POSITIVEInvestigations3/1031/10213/200
DIZZINESSNervous system disorders0/1034/10212/200
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders0/1033/10211/200

Baseline characteristics

Age, Continuous
Age, Continuous(years)Double-Blind Period: Adalimumab 160/80/40 mgDouble-Blind Period: Placebo Followed by Adalimumab 160/80 mgTotal
Mean33.2 ± 10.2432.6 ± 9.5032.9 ± 9.85
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Period: Adalimumab 160/80/40 mgDouble-Blind Period: Placebo Followed by Adalimumab 160/80 mgTotal
Female353065
Male6773140
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-Blind Period: Adalimumab 160/80/40 mgDouble-Blind Period: Placebo Followed by Adalimumab 160/80 mgTotal
Chinese102103205
Crohn's Disease Activity Index (CDAI)
Crohn's Disease Activity Index (CDAI)(units on a scale)Double-Blind Period: Adalimumab 160/80/40 mgDouble-Blind Period: Placebo Followed by Adalimumab 160/80 mgTotal
Mean272.05 ± 48.117274.71 ± 49.055273.38 ± 48.490
High Sensitivity C-Reactive Protein (Hs-CRP)
High Sensitivity C-Reactive Protein (Hs-CRP)(mg/L)Double-Blind Period: Adalimumab 160/80/40 mgDouble-Blind Period: Placebo Followed by Adalimumab 160/80 mgTotal
Mean23.93 ± 24.59527.12 ± 31.52625.53 ± 28.266
Fecal Calprotectin
Fecal Calprotectin(μg/g)Double-Blind Period: Adalimumab 160/80/40 mgDouble-Blind Period: Placebo Followed by Adalimumab 160/80 mgTotal
Mean1481.8 ± 809.291435.4 ± 766.371458.4 ± 786.20
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Chen B, Gao X, Zhong J, Ren J, Zhu X, Liu Z, Wu K, Kalabic J, Yu Z, Huang B, Kwatra N, Doan T, Robinson AM, Chen MH. Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial. Therap Adv Gastroenterol. 2020 Jul 16;13:1756284820938960. doi: 10.1177/1756284820938960. eCollection 2020. PubMed 32733600 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in May 2017, 21 months.

Results were first posted in Jan 2019, 1 year 7 months after primary completion.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 21 months is below that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2015
First posted
Jul 16, 2015
StartActual
Aug 17, 2015
Primary completionActual
May 19, 2017
CompletionActual
Dec 15, 2017
Results first posted
Jan 4, 2019
Last update
Jan 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02499783
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 16, 2015
Start date
Aug 17, 2015
Primary completion
May 19, 2017
Completion
Dec 15, 2017
Results posted
Jan 4, 2019
Last update
Jan 4, 2019

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion